/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Finch Therapeutics Group Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.82 -0.0909(-9.09%) FNCH at 04 Dec 2025 04:32 PM Biotechnology
Lowest Today 1.39
Highest Today 2.22
Today’s Open 1.73
Prev. Close 1.98
52 Week High 16.74
52 Week Low 1.39
Day’s Range: Low 1.39 High 2.22
52-Week Range: Low 1.39 High 16.74
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

Institutional Holdings

Susquehanna International Group, LLP 3.68

Vanguard Group Inc 2.26

Vanguard Institutional Extnd Mkt Idx Tr 1.01

Renaissance Technologies Corp 0.73

Vanguard Total Stock Mkt Idx Inv 0.60

Greenwich Ivy Long-Short Instl 0.47

Ikarian Capital, LLC 0.43

Fidelity Extended Market Index 0.23

Tower Research Capital LLC 0.16

Fidelity Total Market Index 0.10

Bleichroeder LP 0.06

Fidelity Nasdaq Composite Index 0.05

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - L 0.04

Spartan Total Market Index Pool E 0.03

BlackRock Inc 0.02

NT Ext Equity Mkt Idx Fd - NL 0.01

Fidelity Series Total Market Index 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

Northwestern Mutual Wealth Management Co 0.01

Morgan Stanley - Brokerage Accounts 0.01

SSgA U.S. Extended Market Index Class I 0.01

State St US Extended Mkt Indx NL Cl C 0.01

SSgA U.S. Total Market Index Strategy 0.00

State St US Ttl Mkt Indx SL Cl I 0.00

Northern Trust Wilshire 5000 0.00

NT US Market Cap Idx Fd - L 0.00

Royal Bank of Canada 0.00

BlackRock Extended Mkt Composite 0.00

Bank of America Corp 0.00

BNYM Mellon NSL Mkt Completion Fund Inst 0.00

Wells Fargo & Co 0.00

Cutler Group LP 0.00

Moisand Fitzgerald Tamayo, LLC 0.00

UBS Group AG 0.00

Ancora Advisors LLC 0.00

Baupost Group LLC 0.00

LAKE STREET ADVISORS GROUP, LLC 0.00

MSD Partners, L.P. 0.00

Steward Partners Investment Advisory, LLC 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 3.18 M

PB Ratio 0.1424

PE Ratio 0.0

Enterprise Value 11.98 M

Total Assets 71.00 M

Volume 629479

Company Financials

Annual Revenue FY23:115000 0.1M, FY22:861000 0.9M, FY21:18532000 18.5M, FY20:7719000 7.7M, FY19:10154000 10.2M

Annual Profit FY23:null 0.0M, FY22:861000 0.9M, FY21:18532000 18.5M, FY20:7719000 7.7M, FY19:9840000 9.8M

Annual Net worth FY23:-98721000 -98.7M, FY22:-113699000 -113.7M, FY21:-55859000 -55.9M, FY20:-39248000 -39.2M, FY19:-20406000 -20.4M

Quarterly Revenue Q1/2024:0 0.0M, Q4/2023:2845000 2.8M, Q3/2023:0 0.0M, Q2/2023:0 0.0M, Q1/2023:107000 0.1M

Quarterly Profit Q1/2024:-43000 -0.0M, Q4/2023:2801000 2.8M, Q3/2023:null 0.0M, Q2/2023:null 0.0M, Q1/2023:107000 0.1M

Quarterly Net worth Q1/2024:-3876000 -3.9M, Q4/2023:-3041000 -3.0M, Q3/2023:-2416000 -2.4M, Q2/2023:-6950000 -7.0M, Q1/2023:-63939000 -63.9M

Fund house & investment objective

Company Information Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Organisation Biotechnology

Employees 1

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow